Functional Effects of PTPN11 (SHP2) Mutations Causing LEOPARD Syndrome on Epidermal Growth Factor-Induced Phosphoinositide 3-Kinase/AKT/Glycogen Synthase Kinase 3β Signaling

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Molecular and Cellular Biology

• Publication date

  2010-03-22

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/MCB.00646-09PMID 20308328PMCID PMC2863708
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Noonan Syndrome/Leukemia-associated Gain-of-function Mutations in SHP-2 Phosphatase (PTPN11) Enhance Cell Migration and Angiogenesis*

  2009influential reference
• Mutation in SHOC2 promotes aberrant protein N-myristoylation and underlies Noonan-like syndrome with loose anagen hair

  2009cited by this paper
• Oncogenic HRAS mutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome

  2009cited by this paper
• Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair

  2009cited by this paper
• Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: Molecular diversity and associated phenotypic spectrum

  2009cited by this paper
• Phosphatase-defective LEOPARD syndrome mutations in PTPN11 gene have gain-of-function effects during Drosophila development.

  2009cited by this paper
• Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation

  2009cited by this paper
• Epac Mediates &bgr;-Adrenergic Receptor–Induced Cardiomyocyte Hypertrophy

  2008cited by this paper
• Noonan Syndrome-associated SHP-2/Ptpn11 Mutants Enhance SIRPα and PZR Tyrosyl Phosphorylation and Promote Adhesion-mediated ERK Activation*

  2008cited by this paper
• Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome

  2008cited by this paper
• Germline gain-of-function mutations in SOS1 cause Noonan syndrome

  2007cited by this paper
• Ras and Phosphoinositide 3-Kinase: Partners in Development and Tumorigenesis

  2007cited by this paper
• Glycogen Synthase Kinase-3β—Actively Inhibiting Hypertrophy

  2007cited by this paper
• Signal Strength Dictates Phosphoinositide 3-Kinase Contribution to Ras/Extracellular Signal-Regulated Kinase 1 and 2 Activation via Differential Gab1/Shp2 Recruitment: Consequences for Resistance to Epidermal Growth Factor Receptor Inhibition

  2007cited by this paper
• Gab1/Shp2 Recruitment: Consequences for Resistance to EGFR Inhibition

  2007cited by this paper
• Mediating ERK 1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome.

  2007cited by this paper
• Shp2 Knockdown and Noonan/LEOPARD Mutant Shp2–Induced Gastrulation Defects

  2007influential reference
• Glycogen synthase kinase-3beta -- actively inhibiting hypertrophy.

  2007cited by this paper
• Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy

  2007cited by this paper
• Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease.

  2006cited by this paper
• Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction.

  2006influential reference
• Stops along the RAS pathway in human genetic disease

  2006cited by this paper
• Germline KRAS mutations cause Noonan syndrome

  2006cited by this paper
• Gain-of-function/Noonan syndrome SHP-2/Ptpn11 mutants enhance calcium oscillations and impair NFAT signaling

  2006influential reference
• Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome

  2006cited by this paper
• The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

  2006cited by this paper
• The Adaptor Protein Gab1 Couples the Stimulation of Vascular Endothelial Growth Factor Receptor-2 to the Activation of Phosphoinositide 3-Kinase*

  2006cited by this paper
• PTPN11 (Shp2) Mutations in LEOPARD Syndrome Have Dominant Negative, Not Activating, Effects*

  2006cited by this paper
• Reduced phosphatase activity of SHP‐2 in LEOPARD syndrome: Consequences for PI3K binding on Gab1

  2006cited by this paper
• Diverse Biochemical Properties of Shp2 Mutants

  2005cited by this paper
• A Novel Role for Gab1 and SHP2 in Epidermal Growth Factor-induced Ras Activation*

  2005cited by this paper
• cAMP-Binding Protein Epac Induces Cardiomyocyte Hypertrophy

  2005cited by this paper
• Noonan Syndrome Mutation Q79R in Shp2 Increases Proliferation of Valve Primordia Mesenchymal Cells via Extracellular Signal–Regulated Kinase 1/2 Signaling

  2005cited by this paper
• cAMP-Binding Protein Epac Induces Cardiomyocyte Hypertrophy

  2005cited by this paper
• Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors.

  2005cited by this paper
• Mouse model of Noonan syndrome reveals cell type– and gene dosage–dependent effects of Ptpn11 mutation

  2004influential reference
• The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway

  2004cited by this paper
• Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment.

  2004cited by this paper
• Noonan syndrome–associated SHP2/PTPN11 mutants cause EGF‐dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation

  2004influential reference
• Shp2, an SH2-containing Protein-tyrosine Phosphatase, Positively Regulates Receptor Tyrosine Kinase Signaling by Dephosphorylating and Inactivating the Inhibitor Sprouty*

  2004cited by this paper
• Bone morphogenetic proteins negatively control oligodendrocyte precursor specification in the chick spinal cord.

  2002cited by this paper
• Receptor-Specific Regulation of Phosphatidylinositol 3′-Kinase Activation by the Protein Tyrosine Phosphatase Shp2

  2002cited by this paper
• Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer.

  2001cited by this paper
• Activation of cardiac gene expression by myocardin, a transcriptional cofactor for serum response factor.

  2001influential reference
• Cellular function of phosphoinositide 3-kinases: Implications for development, immunity, homeostasis, and cancer

  2001cited by this paper
• Induction-independent Recruitment of CREB-binding Protein to the c-fos Serum Response Element through Interactions between the Bromodomain and Elk-1*

  2001cited by this paper
• GSK3 takes centre stage more than 20 years after its discovery.

  2001influential reference
• Molecular Mechanism for the Shp-2 Tyrosine Phosphatase Function in Promoting Growth Factor Stimulation of Erk Activity

  2000cited by this paper
• A simplified system for generating recombinant adenoviruses.

  1998cited by this paper
• Model SV40-transformed fibroblast lines for metabolic studies of human prosaposin and acid ceramidase deficiencies.

  1997cited by this paper
• Cardiotrophin-1 Activates a Distinct Form of Cardiac Muscle Cell Hypertrophy

  1996cited by this paper
• Glycogen Synthase Kinase 3 (cid:1) Inhibits Myocardin-Dependent Transcription and Hypertrophy Induction Through Site-Specific Phosphorylation

  year unknowninfluential reference

• The pathogenic E139D mutation stabilizes a non‐canonical active state of the multi‐domain phosphatase SHP2

  2025cites this paper
• Interpreting the functional impact of genetic variants: The need for context qualifiers.

  2025cites this paper
• The pathogenic E139D mutation stabilizes a non-canonical active state of the multi-domain phosphatase SHP2

  2025cites this paper
• Genotype–phenotype correlations with autism spectrum disorder-related traits in Noonan syndrome and Noonan syndrome with multiple lentigines: a cross-sectional study

  2025cites this paper
• Proximity-labeling proteomics reveals remodeled interactomes and altered localization of pathogenic SHP2 variants

  2025cites this paper
• Discovery of TK-642 as a highly potent, selective, orally bioavailable pyrazolopyrazine-based allosteric SHP2 inhibitor

  2024cites this paper
• Promising natural products targeting protein tyrosine phosphatase SHP2 for cancer therapy

  2024cites this paper
• Time-dependent effects of BRAF-V600E on cell cycling, metabolism, and function in engineered myocardium

  2024cites this paper
• Sunitinib selectively targets leukemogenic signaling of mutant SHP2 in juvenile myelomonocytic leukemia.

  2023cites this paper
• Atomistic ensemble of active SHP2 phosphatase

  2023cites this paper
• Deletion of PDK_1 Caused Cardiac Malmorphogenesis and Heart Defects Due to Profound Protein Phosphorylation Changes Mediated by SHP_2

  2023cites this paper
• An integrated genetic analysis of epileptogenic brain malformed lesions

  2023cites this paper
• Protein Tyrosine Phosphatase SHP2 in Macrophages Acts as an Antiatherosclerotic Regulator in Mice

  2023cites this paper
• Skeletal defects and bone metabolism in Noonan, Costello and cardio-facio-cutaneous syndromes

  2023cites this paper
• Novel therapeutic perspectives in Noonan syndrome and RASopathies

  2023cites this paper
• Nonreceptor Protein Kinases and Phosphatases Necessary for Auditory Function

  2023cites this paper
• Friend or foe? Unraveling the complex roles of protein tyrosine phosphatases in cardiac disease and development.

  2022cites this paper
• The seventh international RASopathies symposium: Pathways to a cure—expanding knowledge, enhancing research, and therapeutic discovery

  2022cites this paper
• Induced pluripotent stem cells for modeling Noonan, Noonan Syndrome with Multiple Lentigines, and Costello Syndromes

  2022cites this paper
• Endocrine system involvement in patients with RASopathies: A case series

  2022cites this paper
• Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors.

  2022cites this paper
• Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy.

  2022cites this paper
• Integrated in silico MS-based phosphoproteomics and network enrichment analysis of RASopathy proteins

  2021cites this paper
• Low-dose Dasatinib Ameliorates Hypertrophic Cardiomyopathy in Noonan Syndrome with Multiple Lentigines

  2021cites this paper
• Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials.

  2021cites this paper
• The role of the protein tyrosine phosphatase SHP2 in ossification

  2021cites this paper
• RASopathies

  2021cites this paper
• Peptide-based Inhibitors of Protein-Protein Interactions of Src Homology 2 Domain-Containing Phosphatase 2

  2020cites this paper
• Mechanistic insights explain the transforming potential of the T507K substitution in the protein-tyrosine phosphatase SHP2

  2020cites this paper
• Overlapping phenotypes between SHORT and Noonan syndromes in patients with PTPN11 pathogenic variants

  2020cites this paper
• Do the loops in N-SH2 binding cleft truly serve as allosteric switch in SHP2 activation?

  2020cites this paper
• Insulin receptor endocytosis in the pathophysiology of insulin resistance

  2020cites this paper
• Activation of the MAPK pathway (RASopathies) and partial growth hormone insensitivity.

  2020cites this paper
• Therapeutic potential of targeting SHP2 in human developmental disorders and cancers.

  2020cites this paper
• The loops of the N-SH2 binding cleft do not serve as allosteric switch in SHP2 activation

  2020cites this paper
• Compound heterozygosity for PTPN11 variants in a subject with Noonan syndrome provides insights into the mechanism of SHP2‐related disorders

  2020cites this paper
• Targeting Oncogenic Src Homology 2 Domain-Containing Phosphatase 2 (SHP2) by Inhibiting its Protein-Protein Interactions

  2020cites this paper
• Activating MRAS mutations cause Noonan syndrome associated with hypertrophic cardiomyopathy.

  2020cites this paper
• Etude des anomalies du métabolisme énergétique associées au syndrome de Noonan

  2019cites this paper
• RASopathy-associated Cardiomyopathy

  2019influential citation
• LEOPARD Syndrome with PTPN11 Gene Mutation in Three Family Members Presenting with Different Phenotypes

  2019cites this paper
• Normal Growth despite Combined Pituitary Hormone Deficiency

  2019cites this paper
• The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway.

  2018cites this paper
• Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner

  2018cites this paper
• UNVEILING VESTIGES OF MAN-MADE MODIFICATIONS ON MOLECULAR-BIOLOGICAL EXPERIMENT IMAGES

  2018cites this paper
• Noonan syndrome-causing SHP2 mutants impair ERK-dependent chondrocyte differentiation during endochondral bone growth

  2018cites this paper
• High-quality SNPs from genic regions highlight introgression patterns among European white oaks (Quercus petraea and Q. robur)

  2018cites this paper
• Sulforaphane-mediated inhibition of SHP2 as a potential pharmacotherapy for Noonan syndrome

  2018cites this paper
• Clinical Presentation and Natural History of Hypertrophic Cardiomyopathy in RASopathies.

  2018cites this paper
• Spinal SHP2 Contributes to Exaggerated Incisional Pain in Adult Rats Subjected to Neonatal and Adult Incisions via PI3K.

  2018influential citation
• MAPK and PI3K signaling: At the crossroads of neural crest development.

  2018cites this paper
• Impact de la protéine SHP2 associé au syndrome de Noonan sur le métabolisme glucidique

  2018influential citation
• A ERK/RSK‐mediated negative feedback loop regulates M‐CSF–evoked PI3K/AKT activation in macrophages

  2017cites this paper
• The Interplay of Biomechanics, Tissue Polarity and Collective Migration as it Contributes to Early Heart Organogenesis

  2017cites this paper
• Congenital heart disease and genetic syndromes: new insights into molecular mechanisms

  2017cites this paper
• Identification of demethylincisterol A3 as a selective inhibitor of protein tyrosine phosphatase Shp2

  2017cites this paper
• Structural, Functional, and Clinical Characterization of a Novel PTPN11 Mutation Cluster Underlying Noonan Syndrome

  2017cites this paper
• Heterozygous deletion of AKT1 rescues cardiac contractility, but not hypertrophy, in a mouse model of Noonan Syndrome with Multiple Lentigines.

  2017cites this paper
• MECHANISMS IN ENDOCRINOLOGY: Novel genetic causes of short stature.

  2016cites this paper
• Alterations in the phosphoproteomic profile of cells expressing a non-functional form of the SHP2 phosphatase.

  2016cites this paper
• Síndrome LEOPARD diagnosticado en un adulto

  2016cites this paper
• Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.

  2016cites this paper
• Growth patterns of patients with Noonan syndrome: correlation with age and genotype.

  2016cites this paper
• Developmental SHP2 dysfunction underlies cardiac hypertrophy in Noonan syndrome with multiple lentigines.

  2016cites this paper
• Identification of Top-ranked Proteins within a Directional Protein Interaction Network using the PageRank Algorithm: Applications in Humans and Plants.

  2016cites this paper
• Cardiomyopathies in Noonan syndrome and the other RASopathies.

  2015cites this paper
• Pathogenesis of multiple lentigines in LEOPARD syndrome with PTPN11 gene mutation.

  2015cites this paper
• Pharmacological targeting of AKAP-directed compartmentalized cAMP signalling.

  2015cites this paper
• The Q510E mutation in Shp2 perturbs heart valve development by increasing cell migration.

  2015cites this paper
• SHP2 sails from physiology to pathology.

  2015cites this paper
• Shp2 in Forebrain Neurons Regulates Synaptic Plasticity, Locomotion, and Memory Formation in Mice

  2015cites this paper
• Noonan Syndrome with Multiple Lentigines: Insights into Hypertrophy and Hypercontractility

  2015cites this paper
• Noonan Syndrome and Other RAS/MAPK Pathway Syndromes

  2015cites this paper
• Elevated Ca2+ transients and increased myofibrillar power generation cause cardiac hypercontractility in a model of Noonan syndrome with multiple lentigines.

  2015cites this paper
• DEV106310 1..10

  2014influential citation
• Molecular Basis of Gain-of-Function LEOPARD Syndrome-Associated SHP2 Mutations

  2014cites this paper
• SHP-2 regulates growth factor dependent vascular signalling and function.

  2014cites this paper
• Applying next generation sequencing to skeletal development and disease

  2014cites this paper
• DEV106310 1961..1970

  2014influential citation
• Global Proteomic Assessment of Classical Protein-tyrosine Phosphatases

  2014cites this paper
• Distinct and Overlapping Functions of ptpn11 Genes in Zebrafish Development

  2014cites this paper
• Noonan and LEOPARD syndrome in zebrafish : molecular mechanisms and cardiac development

  2014cites this paper
• Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.

  2014cites this paper
• LEOPARD syndrome-associated SHP2 mutation confers leanness and protection from diet-induced obesity

  2014cites this paper
• Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish

  2014cites this paper
• Regulation of bone and skeletal development by the SHP-2 protein tyrosine phosphatase.

  2014cites this paper
• Overexpression of SHP2 tyrosine phosphatase promotes the tumorigenesis of breast carcinoma.

  2014cites this paper
• Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11)

  2014cites this paper
• Deletion of SHP-2 in mesenchymal stem cells causes growth retardation, limb and chest deformity, and calvarial defects in mice

  2013cites this paper
• Role of the SHP2 Protein Tyrosine Phosphatase in Cardiac Metabolism

  2013cites this paper
• PI3K in juvenile myleomonocytic leukemia

  2013cites this paper
• New Approaches to Prevent LEOPARD Syndrome-associated Cardiac Hypertrophy by Specifically Targeting Shp2-dependent Signaling*

  2013cites this paper
• Mécanismes moléculaires impliqués en aval du récepteur de l’hormone de croissance

  2012cites this paper
• Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature

  2012cites this paper
• Interleukin-6 signalling: more than Jaks and STATs.

  2012cites this paper
• ROCKs cause SHP-wrecks and broken hearts

  2012cites this paper
• The neural crest in cardiac congenital anomalies.

  2012cites this paper
• The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling.

  2012cites this paper
• Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.

  2011cites this paper
• LEOPARD-type SHP2 mutant Gln510Glu attenuates cardiomyocyte differentiation and promotes cardiac hypertrophy via dysregulation of Akt/GSK-3β/β-catenin signaling.

  2011influential citation